The Second Wave: What Ozempic Might Actually Be Good For

Ozempic and its chemical cousins made their name as weight-loss drugs. Increasingly, that may turn out to be the least interesting thing about them.

A massive VA-linked study led by researchers at the Veterans Affairs St. Louis Health Care System, analyzing records from over 100 million U.S. patients, found that GLP-1 drugs were associated with reduced risks of substance abuse disorders, suicidal ideation, schizophrenia, and other psychotic disorders — alongside lower risk of neurocognitive disorders like Alzheimer's and dementia, infections, liver cancer, and even life-threatening blood clots. That's not a narrow side benefit; the study identified reduced risk across 42 separate health conditions tied to these medications.

The heart data is now some of the most solid evidence in the entire GLP-1 story. A major international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term. That builds on earlier randomized trial evidence: in the SELECT trial of more than 17,000 adults with heart disease and obesity but not diabetes, semaglutide reduced major cardiovascular events — cardiovascular death, heart attack, and stroke — by roughly 20 percent, a result strong enough that the FDA approved semaglutide specifically to treat cardiovascular disease in overweight or obese adults in March 2024.

The dementia angle is more contested, but increasingly hard to dismiss. A 2025 cohort study in JAMA Network Open, analyzing data from more than 60,000 adults with type 2 diabetes and obesity, found that patients starting semaglutide or tirzepatide had significantly lower risk of developing dementia, stroke, and all-cause mortality over seven years of follow-up, with the strongest effects in adults over 60, women, and people with a BMI of 30 to 40. Separately, Oxford University researchers evaluating more than 60,000 patient records found Ozempic wasn't linked to increased risk across 22 different brain or psychiatric disorders, including dementia and drug addiction, when compared to other diabetes medications. Not every trial has cooperated with the theory, though — Novo Nordisk recently reported disappointing results from two large randomized trials testing semaglutide specifically in patients who already had mild cognitive impairment or dementia, suggesting any protective effect may work better as prevention than treatment.

The addiction research, while newer, follows a similar pattern of surprising consistency across independent datasets, showing up in the VA study, the Oxford analysis, and smaller trials alike — enough that clinicians researching the space now describe the addiction and mental health angle as "real but still maturing" territory, distinct from the heart and kidney benefits that already rest on solid randomized evidence.

None of this makes GLP-1 drugs risk-free. The same research documenting these benefits has also flagged increased risk for kidney stones and low blood pressure, and separate work has tied the drugs to pancreatitis and gastrointestinal complications. And a Cleveland Clinic study comparing outcomes directly found that weight-loss surgery still outperformed GLP-1 medications for long-term improvements in heart, kidney, and eye complications over a decade.

Even accounting for those caveats, the sheer range of conditions now under study — heart disease, kidney disease, liver disease, sleep apnea, substance abuse, psychosis risk, and dementia — has left researchers describing GLP-1s as something closer to a general metabolic reset button than a narrow diabetes or obesity treatment. The theory gaining traction: by lowering the chronic inflammation and metabolic dysfunction that quietly drives an enormous share of unrelated disease, these drugs may be doing far more in the body than anyone initially designed them to do — which is exactly why a class of medicine that started as a diabetes treatment is now being studied as a candidate for nearly every major disease of aging.